CD19 and neoplasm: Interestingly, the lower tumor growth observed in the NT-NK group compared to CD19 CAR-NK group and eventual tumor elimination in NT-NKs diverged from the expectation that NT-NKs would perform worse than CAR-engineered NK cells.